Search
Gallium nitrate
go.drugbank.com/drugs/DB05260ApprovedInvestigational[L47726] Apart from cancer-related hypercalcemia, gallium nitrate has been studied in arthritis, autoimmune disorders, and tumours.[A260830] … [A17097] GANITE, a product of gallium nitrate previously used to treat cancer-related hypercalcemia, was discontinued from marketing in the US for reasons other than safety or effectiveness.
AVN-944
go.drugbank.com/drugs/DB05500InvestigationalAVN944 has been associated with cancer cell death in clinical trials. It is being investigated for the treatment of patients with advanced hematologic malignancies. … AVN944 is a biotech drug that demonstrated a statistically meaningful impact on IMPDH and other proteins that are critical to activities in cancer cells, including nucleotide biosynthesis, energy and metabolism
Olopatadine
go.drugbank.com/drugs/DB00768ApprovedAn ophthalmic solution of olopatadine was approved by the FDA and European Union for the treatment of seasonal and perennial allergic conjunctivitis in 1996 and 2002, respectively. … [A179809] Olopatadine is used for the symptomatic treatment of ocular itching associated with allergic conjunctivitis in ophthalmic formulations and seasonal allergic rhinitis in intranasal formulations
Pralsetinib
go.drugbank.com/drugs/DB15822ApprovedInvestigationalAlthough multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated … It is currently marketed under the brand name GAVRETO™ by Blueprint Medicines.[L15986]
Benzhydrocodone
go.drugbank.com/drugs/DB15465Approved[A182177] Benzhydrocodone is indicated for use in the short-term management of pain. … It was first approved by the FDA in February 2018 in combination with [acetaminophen] under the trade name Apadaz, marketed by KVK Tech and developed by KemPharm.[L7859,L7862]
Palovarotene
go.drugbank.com/drugs/DB05467Approved[A244920] Palovarotene was approved for use in Canada in January 2022 for the management of heterotopic ossification (HO) in patients with FOP, representing the first global approval for any FOP therapy … [A244920] FOP is caused by a gain-of-function mutation in the ACVR1/ALK2 gene which results in progressive heterotopic ossification, a process wherein connective tissues (e.g. skeletal muscle, ligaments
Choline salicylate
go.drugbank.com/drugs/DB14006ApprovedNutraceuticalThis drug is also a main ingredient in teething gels to relieve pains associated with tooth growth in the infant population [L2134]. … It is used to treat arthritis in both children and adults. This medicine can also be used for fever [L2129].
Belnacasan
go.drugbank.com/drugs/DB05507InvestigationalVX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus. … VX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase-1 (VRT-043198).
Sorafenib
go.drugbank.com/drugs/DB00398ApprovedInvestigational[A255852] First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma … It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis.
Synonyms: N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea, 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamideAntithrombin Alfa
go.drugbank.com/drugs/DB11166ApprovedAntithrombin Alfa is a recombinant antithrombin , an anticoagulant, that is used for the prevention of thromboembolic events in patients that have hereditary deficiency of antithrombin in high risk situations